John Butler Email

CEO/CSO and Founder . QuantumCyte

Current Roles

Employees:
13
Revenue:
$2M
About
Advancing Molecular Pathology at the Cellular Level Quantumcyte’s NextGen Microdissection technology is a scalable, cost effective and automated system that enriches and extracts the molecular material directly from targeted cells delivering high accuracy results. Our system utilizes typical biopsies such as FFPE sections and cryopreserved tissues mounted on standard microscope slides. Further, CytoMask technology can process manually annotated slides and digital images, as well as your automatically annotated digital pathology images. The NextGen Microdissection output is compatible with most off-the-shelf NGS gene panels thus improving the specificity of your existing validated workflow. The Quantumcyte workflow combines identifying clinically important areas (CIAs), masking nonessential areas, and the extraction of nucleic acid or protein from the CIAs. The resulting extracts can then be processed via standard techniques including but not limited to qPCR, Sanger sequencing, NGS sequencing, or proteomic analysis. For questions and inquiries, please contact us at info@quantumcyte.com,
QuantumCyte Address
428 Oakmead Parkway
Sunnyvale, CA
QuantumCyte Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.